216 related articles for article (PubMed ID: 35410757)
21. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy.
Aldoss I; Shan H; Yang D; Clark MC; Malki MA; Aribi A; Agrawal V; Sandhu K; Salhotra A; Pourhassan H; Koller P; Ali H; Artz A; Karras N; Pawlowska AB; Murphy L; Palmer J; Stein A; Marcucci G; Pullarkat V; Nakamura R; Forman SJ
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38876428
[TBL] [Abstract][Full Text] [Related]
22. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
[TBL] [Abstract][Full Text] [Related]
23. Early versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemia.
Chen GL; Liu H; Zhang Y; Thomas J; Ross M; Wang ES; Block AW; Sait S; Deeb G; Wallace P; Wetzler M; Hahn T; McCarthy PL
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1369-74. PubMed ID: 24867777
[TBL] [Abstract][Full Text] [Related]
24. SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia.
Jen WY; Jabbour E; Kantarjian HM; Short NJ
Clin Lymphoma Myeloma Leuk; 2024 Mar; ():. PubMed ID: 38538495
[TBL] [Abstract][Full Text] [Related]
25. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
[TBL] [Abstract][Full Text] [Related]
26. Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease.
Bourlon C; Lacayo-Leñero D; Inclán-Alarcón SI; Demichelis-Gómez R
Curr Oncol Rep; 2018 Mar; 20(4):36. PubMed ID: 29577208
[TBL] [Abstract][Full Text] [Related]
27. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C
J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079
[TBL] [Abstract][Full Text] [Related]
28. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Lee CJ; Savani BN; Mohty M; Gorin NC; Labopin M; Ruggeri A; Schmid C; Baron F; Esteve J; Giebel S; Ciceri F; Nagler A
Bone Marrow Transplant; 2019 Apr; 54(4):519-530. PubMed ID: 30104717
[TBL] [Abstract][Full Text] [Related]
29. Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.
Solomon SR; Sizemore CA; Zhang X; Brown S; Holland HK; Morris LE; Solh M; Bashey A
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1816-1822. PubMed ID: 27453362
[TBL] [Abstract][Full Text] [Related]
30. Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia.
Al Malki MM; Aldoss I; Stiller T; Nakamura R; Snyder DS; Forman SJ; Pullarkat V
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):519-522. PubMed ID: 27394652
[TBL] [Abstract][Full Text] [Related]
31. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
32. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
Front Immunol; 2022; 13():879030. PubMed ID: 35558072
[TBL] [Abstract][Full Text] [Related]
33. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
[TBL] [Abstract][Full Text] [Related]
34. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.
Badar T; Szabo A; Litzow M; Burkart M; Yurkiewicz I; Dinner S; Hefazi M; Shallis RM; Podoltsev N; Patel AA; Curran E; Wadleigh M; Balasubramanian S; Yang J; Arslan S; Aldoss I; Mattison R; Cenin D; Siebenaller C; Advani A; Liedtke M; Atallah E
Bone Marrow Transplant; 2021 Aug; 56(8):1998-2004. PubMed ID: 33824440
[TBL] [Abstract][Full Text] [Related]
35. Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes.
Khazal S; Kebriaei P
Leuk Lymphoma; 2021 Dec; 62(12):2831-2844. PubMed ID: 34080951
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis.
Derigs P; Bethge WA; Krämer I; Holtick U; von Tresckow B; Ayuk F; Penack O; Vucinic V; von Bonin M; Baldus C; Mougiakakos D; Wulf G; Schnetzke U; Stelljes M; Fante M; Schroers R; Kroeger N; Dreger P;
Transplant Cell Ther; 2023 Dec; 29(12):750-756. PubMed ID: 37709204
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
[TBL] [Abstract][Full Text] [Related]
38. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
Logan AC; Vashi N; Faham M; Carlton V; Kong K; Buño I; Zheng J; Moorhead M; Klinger M; Zhang B; Waqar A; Zehnder JL; Miklos DB
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1307-13. PubMed ID: 24769317
[TBL] [Abstract][Full Text] [Related]
40. A systematic review of outcomes after stem cell transplantation in acute lymphoblastic leukemia with or without measurable residual disease.
Shah S; Martin A; Turner M; Cong Z; Zaman F; Stein A
Leuk Lymphoma; 2020 May; 61(5):1052-1062. PubMed ID: 31960716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]